Galderma Pharmaceutical Expands in Quebec
Location Canada 2010
Galderma, which produces the skin care line Cetaphil, received more than $38 million from Investissement Quebec, the province's investment program, which targets product development projects by Quebec companies. The sum includes a non-refundable $3.8 million financial contribution that will help Galderma modernize and expand its drug manufacturing plant in Bai-d'Urfe.
"The government's support was a decisive factor in Galderma's decision to locate its center of excellence in Quebec," says Michel Sauvageau, manager of the Bai-d'Urfe plant. "In response to the progress of emerging countries in biopharmaceuticals, this investment in our manufacturing facility will increase its capacity and make it truly state-of-the-art."
The funds will also allow Galderma to consolidate 240 positions and create 30 new, specialized jobs.
Most Read
-
-
Trends in Office and Industrial Parks
Q4 2020
-
The Future of the Workforce Is a “Better Normal”
Workforce Q4 2020
-
Another Look at Rural Economies
Q4 2020
-
Supply Chain Execs Respond as Pandemic Creates E-Commerce Surge
Q4 2020
-
Recruiting and Retaining Today’s Manufacturing Workforce
Workforce Q4 2020
-
Cold Storage Is Hotter Than Ever
Q4 2020